<DOC>
	<DOCNO>NCT01839643</DOCNO>
	<brief_summary>In study , investigator propose assess non-hormonal agent absorb local route ( vaginal ) observe effect follicular development . This study include 3 menstrual cycle , begin one menstrual control cycle , follow one menstrual cycle meloxicam ring administration finish another control menstrual cycle . Meloxicam administer via vaginal ring two dos 2.4 g 3.0 g/ ring one menstrual cycle . Safety study absorption assess . Also investigator study effect follicular development maintain ovarian cyclicity , well show recent study oral administration .</brief_summary>
	<brief_title>Assessment Vaginal Ring With Meloxicam Ovarian Cycle Fertile Women</brief_title>
	<detailed_description />
	<mesh_term>Meloxicam</mesh_term>
	<mesh_term>Anti-Inflammatory Agents , Non-Steroidal</mesh_term>
	<criteria>Fertile woman Regular menstrual cycle Surgically sterilize Without breastfeed Haemoglobin 11g/dL Willing participate study Allergy meloxicam NSAID Allergy silicone polymer Vaginal discharge non diagnosticated History shock toxic syndrome History : gastrointestinal , bleeding , renal , liver , heart , brain , clot , endocrine pulmonary disorder</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>pharmacokinetic</keyword>
</DOC>